Company intelligence / Profile preview

SpringTree

Stamford, Connecticut, United States

Ownership: Private
Employees: ~350
Development stage: Other

Overview

SpringWorks Therapeutics is a commercial-stage biopharmaceutical company focused on developing therapies for severe rare diseases and cancer. Spun out from Pfizer in 2017, the company utilizes a precision medicine approach to target key genetic drivers of disease. Its lead product, Ogsiveo (nirogacestat), is the first and only FDA-approved treatment for adult patients with progressing desmoid tumors. SpringWorks is also advancing mirdametinib, a MEK inhibitor, in late-stage clinical trials for neurofibromatosis type 1-associated plexiform neurofibromas, alongside a robust pipeline of other targeted oncology candidates.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

PfizerGSKJohnson & JohnsonRegeneronAbbVie

Beyond the preview

Go deeper on SpringTree.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SpringTree.

Explore the full profile